🔎 Trials Near Me

Domov › Rak (vse vrste) › Utah › Salt Lake City

Klinične študije za Rak (vse vrste) v Salt Lake City, UT

27 študij za Rak (vse vrste) išče udeležence na lokacijah v Salt Lake City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

Vključevanje udeležencevFaza 1/2
  • Intermountain - Primary Children's Hospital ( Site 4014), Salt Lake City
1 Month – 17 Years · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07630974

SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care

Vključevanje udeležencev
  • Huntsman Cancer Institute/ University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07410689

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Vključevanje udeležencevFaza 3
  • Utah Cancer Specialists Cancer Center - Medical Oncology, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06901531

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Vključevanje udeležencevFaza 2
  • Intermountain Healthcare, Salt Lake City
Starost 12 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT02693535

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Vključevanje udeležencevFaza 2/3
  • University of Utah - Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare - LDS Hospital, Salt Lake City
Vse starosti · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT03435796

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Vključevanje udeležencevFaza 1/2
  • Intermountain - Primary Children's Hospital ( Site 3014), Salt Lake City
1 Month – 17 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06941272

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Vključevanje udeležencevFaza 2
  • Huntsman Cancer Institute - University of Utah Health, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT04996875

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Vključevanje udeležencevFaza 1/2
  • Huntsman Cancer Institute /ID# 271618, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06953960

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Vključevanje udeležencevFaza 1/2
  • Huntsman Cancer Institute, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT06634589

Project: Every Child for Younger Patients With Cancer

Vključevanje udeležencevOpazovalna študija
  • Primary Children's Hospital, Salt Lake City
Do 25 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT02402244

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Vključevanje udeležencevFaza 3
  • University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT05335928

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Vključevanje udeležencevFaza 3
  • University of Utah Sugarhouse Health Center, Salt Lake City
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06580314

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Vključevanje udeležencevFaza 1/2
  • Huntsman Cancer Institute /ID# 272575, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 21. jul. 2026 · NCT06892522

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Vključevanje udeležencevFaza 1
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 15. jul. 2026 · NCT06657144

Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions

Vključevanje udeležencev
  • Huntsman Cancer Institute at The University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 10. jul. 2026 · NCT07556380

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

Vključevanje udeležencev
  • VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City
Starost 18–75 · Vsi spoli · Posodobljeno 17. jun. 2026 · NCT05486572

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

Vključevanje udeležencev
  • University of Utah Huntsman Cancer Institute (HCI), Salt Lake City
  • University of Utah Primary Children's Hospital, Salt Lake City
Starost 15–29 · Vsi spoli · Posodobljeno 22. maj 2026 · NCT05958316

Galleri® in the Medicare Population.

Vključevanje udeležencevVabljeni zdravi prostovoljci
  • HCA Healthcare St. Marks, Salt Lake City
Starost 50 in več · Vsi spoli · Posodobljeno 22. maj 2026 · NCT05673018

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Vključevanje udeležencevFaza 2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT01042379

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Vključevanje udeležencev
  • George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 30. apr. 2026 · NCT05297734

Improving Health Insurance Literacy Among Young Adult Cancer Survivors

Vključevanje udeležencev
  • University of Utah, Salt Lake City
Starost 26–45 · Vsi spoli · Posodobljeno 28. apr. 2026 · NCT05829070

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Vključevanje udeležencevFaza 1/2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 16. apr. 2026 · NCT03328078

Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type

Vključevanje udeležencev
  • Huntsman Cancer Institute, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 26. nov. 2025 · NCT06484179

Childhood Cancer Predisposition Study (CCPS)

Vključevanje udeležencevOpazovalna študija
  • Primary Children's Hospital, Salt Lake City
Vse starosti · Vsi spoli · Posodobljeno 29. okt. 2025 · NCT04511806

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Vključevanje udeležencevOpazovalna študija
  • Massive Bio SYNERGY-AI site, Salt Lake City
Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Vključevanje udeležencevOpazovalna študija
  • Utah Cancer Specialists, Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2025 · NCT05234177

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Vključevanje udeležencev
  • Huntsman Cancer Institute (The University of Utah), Salt Lake City
Starost 18 in več · Vsi spoli · Posodobljeno 27. nov. 2024 · NCT03860883

Študije za Rak (vse vrste) v drugih mestih

Druge študije v Salt Lake City

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.